E
enGene Therapeutics Inc.
Biotechnology: Biological Products (No Diagnostic Substances) company
Key Metrics of enGene Therapeutics Inc.
Revenue—FY 2023
Operating income−$26.1M▼ 34.1% YoY
Net profit−$99.9M▼ 308.5% YoY
Shareholders' equity$62.4M
Market cap$97.2MENGN · $1.45
Competitors10identified
About enGene Therapeutics Inc.
Sectors
Company details
- Listed
- Nasdaq: ENGN
Operational Areas of enGene Therapeutics Inc.
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameenGene Therapeutics Inc.
TickerENGN
ExchangeNasdaq
CountryCanada
SEC CIK0001980845
Listed since—
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Website—
US market & SEC filings
ENGN · Nasdaq · SEC CIK 0001980845
Last price · 03 Nov 2026
$1.45
−5.23%
Market cap$97.2M
P/E0.0On FY 2023 diluted EPS
Volume587,187
SectorHealth CareBiotechnology: Biological Products (No Diagnostic Substances)
Country · IPOCanada
ENGN share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of enGene Therapeutics Inc.
Competitors10identified
Countries3most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Global IT Services & Consulting · IT Services & Software | retisoft.com | — | Canada | |
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | gsk.com | 2022 | United Kingdom | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
 Becton Dickinson |
Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.